IceCure Medical (ICCM) Common Equity (2020 - 2026)

IceCure Medical (ICCM) has 7 years of Common Equity data on file, last reported at $8.5 million in Q1 2026.

• On a quarterly basis, Common Equity rose 41.57% year-over-year to $8.5 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 41.57% increase from a year earlier, with the FY2025 full-year figure at $9.1 million, up 31.15% from the prior year.
• Common Equity for Q1 2026 stood at $8.5 million, down from $9.1 million in the prior quarter.
• Over the last five years, Common Equity for ICCM reached as high as $25.4 million in Q4 2022 and fell as low as $2.9 million in Q2 2025.
• Historically, Common Equity has averaged $13.2 million across 5 years, with a median of $11.6 million in 2024.
• Across the five-year window, Common Equity sank 72.75% in 2025 and soared 41.57% in 2026, its largest moves.
• Year by year, Common Equity stood at $25.4 million in 2022, then sank by 52.16% to $12.2 million in 2023, then slumped by 43.26% to $6.9 million in 2024, then jumped by 31.15% to $9.1 million in 2025, then dropped by 6.15% to $8.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $8.5 million in Q1 2026, $9.1 million in Q4 2025, and $9.3 million in Q3 2025.